New drug QLS7305 tested in healthy volunteers – first step for future therapies
NCT ID NCT07313150
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial will test the safety and tolerability of QLS7305, an investigational drug, in 60 healthy Chinese adults. Participants will receive either single or multiple doses of the drug or a placebo, along with preventive antibiotics. The study focuses on how the body processes the drug and its effects on the immune system, with no direct treatment benefit for volunteers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QLS7305 injection
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, so it is not designed to test any treatment effect. The drug may prove unsafe or ineffective in future patient studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can paying attention to your body rewire your brain waves in 30 minutes?
- New lung imaging technique uses inhaled gas to see inside your lungs
- Quinoa cookie trial: a tasty way to fight obesity?
- New RNA drug ORN252 tested in humans for first time
- Scientists test drug binding in healthy lungs to guide future treatments
- New antibody drug aims to regrow hair – first human trial underway